ITAT rules on pricing method of generic active pharmaceutical ingredients (API)

Rohan Phatarphekar and Manish Bafna, of KPMG, dissect the Mumbai ITAT ruling in the case of Serdia Pharmaceuticals and explain why APIs can constitute a comparable uncontrolled price (CUP) for the import of drugs when the patent has expired.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: